Form 4: Tenaya Therapeutics' Chief Scientific Officer, Timothy Hoey, Reports Stock and Option Grants

Timothy Hoey, Chief Scientific Officer of Tenaya Therapeutics, reports the acquisition of restricted stock units and stock options in the company.

Summary

• On February 23, 2024, Timothy Hoey, the Chief Scientific Officer of Tenaya Therapeutics, Inc., reported the acquisition of 12,500 shares of common stock through restricted stock units and an option to buy 75,000 shares.
• The restricted stock units were granted under the company's 2021 Equity Incentive Plan and will vest in installments starting August 15, 2024.
• The stock options, also granted under the 2021 Equity Incentive Plan, have an exercise price of $5.22 and will vest monthly starting one month after the transaction date, February 23, 2024.
• Following these transactions, Hoey beneficially owns 248,646 shares of Tenaya Therapeutics, Inc. common stock and options for 75,000 shares.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. It reflects standard executive compensation practices, indicating confidence in the company's future.

Positives

• The grant of restricted stock units and stock options to the Chief Scientific Officer aligns his interests with those of the shareholders.
• The vesting schedules for both the restricted stock units and stock options incentivize long-term commitment and performance.

Industry Context

This filing is a routine disclosure related to executive compensation and is common in publicly traded companies. It reflects standard practices for incentivizing key personnel.

Comparison to Industry Standards

• Equity grants are a standard component of executive compensation packages in the biotechnology industry.
• Companies like Amgen, Gilead Sciences, and Biogen also utilize stock options and restricted stock units to align executive incentives with shareholder value.
• The vesting schedules described are typical for such grants, designed to retain key employees over a multi-year period.

Stakeholder Impact

• The equity grants align management's interests with those of shareholders, potentially driving long-term value creation.
• Employees may view the grants as a positive sign of the company's commitment to its leadership.

Key Dates